Joseph M. Busky retired as Chief Financial Officer at QuidelOrtho Corp.
“Mr. Young will succeed Joseph M. Busky, who previously announced his plans to retire”
QuidelOrtho Corp — fact timeline
Source-grounded facts extracted from QuidelOrtho Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Micah Young was appointed as Chief Financial Officer at QuidelOrtho Corp.
“The Board of Directors of QuidelOrtho Corporation (the “Company”) has appointed Micah Young to serve as the Company’s Chief Financial Officer and principal financial officer, effective as of July 6, 2026”
QuidelOrtho Corp shareholders approved Ratification of KPMG LLP as independent auditor for fiscal year 2026 at the 2026-06-16 meeting.
“The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year by the votes set forth in the table below:”
QuidelOrtho Corp shareholders approved Advisory vote on executive compensation at the 2026-06-16 meeting.
“The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers by the votes set forth in the table below:”
QuidelOrtho Corp shareholders approved Election of ten director nominees at the 2026-06-16 meeting.
“The Company's stockholders elected the ten director nominees to the Company's Board of Directors by the votes set forth in the table below:”
QuidelOrtho Corp reported first quarter ended March 29, 2026 results: revenue $620 million. Guidance lowered.
“Key First Quarter 2026 Results: (all comparisons are to the prior year period) • Total revenu e was $620 million , as reported ◦ Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.”
QuidelOrtho Corp reported first quarter of 2026, ended March 29, 2026 results: revenue $615-$620 million. Guidance reaffirmed.
“on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 Revenue The Company currently expects preliminary unaudited revenue, as reported, of $615-$620 million for the first quarter of 2026. This preliminary unaudited revenue was primarily driven by a weaker respiratory season, with U.S. Influenza-like Illness visits down”
QuidelOrtho Corp incurred revolving credit of $700.0 million revolving credit facility with Bank of America, N.A. at Term SOFR plus 2.25% per annum maturing August 21, 2030.
“Loan A Facilities”), (iii) a $1.45 billion senior secured term loan B facility (the “Term Loan B”; collectively with the Term Loan A Facilities, the “Term Loans”) and (iv) a $700.0 million revolving credit facility (the “Revolving Credit Facility”; together with the Term Loans, the “Financing”). The Financing is guaranteed by certain material domestic subsidiaries”
QuidelOrtho Corp incurred term loan of $1.45 billion senior secured term loan B facility with Bank of America, N.A. at Term SOFR plus 4.00% per annum maturing August 21, 2032.
“Loan A”), (ii) a $100.0 million senior secured delayed draw term loan A facility (the “DDTL Term Loan A”; together with the Term Loan A, the “Term Loan A Facilities”), (iii) a $1.45 billion senior secured term loan B facility (the “Term Loan B”; collectively with the Term Loan A Facilities, the “Term Loans”) and (iv) a $700.0 million revolving credit facility (the”
QuidelOrtho Corp incurred term loan of $100.0 million senior secured delayed draw term loan A facility with Bank of America, N.A. at Term SOFR plus 2.25% per annum maturing August 21, 2030.
“the “Lenders”). Pursuant to the Credit Agreement, the Lenders provided the Company with (i) a $1.15 billion senior secured term loan A facility (the “Term Loan A”), (ii) a $100.0 million senior secured delayed draw term loan A facility (the “DDTL Term Loan A”; together with the Term Loan A, the “Term Loan A Facilities”), (iii) a $1.45 billion senior secured term”
QuidelOrtho Corp incurred term loan of $1.15 billion senior secured term loan A facility with Bank of America, N.A. at Term SOFR plus 2.25% per annum maturing August 21, 2030.
“and the other lenders and L/C issuers party thereto (together with Bank of America, the “Lenders”). Pursuant to the Credit Agreement, the Lenders provided the Company with (i) a $1.15 billion senior secured term loan A facility (the “Term Loan A”), (ii) a $100.0 million senior secured delayed draw term loan A facility (the “DDTL Term Loan A”; together with the Term”
QuidelOrtho Corp engaged KPMG LLP as its auditor.
“on February 28, 2025, the Audit Committee approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 28, 2025.”
QuidelOrtho Corp dismissed Ernst & Young LLP as its auditor.
“The Company invited several public accounting firms to participate in this process, including Ernst & Young LLP (“EY”), the Company’s independent registered public accounting firm for the fiscal year ended December 29, 2024. As a result of this process, on February 28, 2025, the Audit Committee approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 28, 2025. This action effectively dismissed E&Y as the Company’s independent registered public accounting firm, effective as of February 28, 2025.”
Joseph M. Busky changed role as Chief Financial Officer at QuidelOrtho Corp.
“Joseph M. Busky, the Company’s Chief Financial Officer, assuming additional responsibilities, including oversight of the Company’s Information Technology function, on November 18, 2024”
Philip McLellan was appointed as Chief Operations Officer at QuidelOrtho Corp.
“the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer (“COO”), effective November 15, 2024.”
Philip McLellan was appointed as Chief Operations Officer at QuidelOrtho Corp.
“In addition, the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer, effective as of the Effective Date.”
Robert J. Bujarski was terminated as Executive Vice President and Chief Operating Officer at QuidelOrtho Corp.
“The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).”
Michael S. Iskra was terminated as Executive Vice President and Chief Commercial Officer at QuidelOrtho Corp.
“The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).”
QuidelOrtho Corp shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 at the 2024-05-14 meeting.
“Proposal No. 3 The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's 2024 fiscal year by the votes set forth in the table below: Votes For Votes Against Abstentions 61,334,670 1,022,808 866,988”
QuidelOrtho Corp shareholders approved Advisory vote on compensation of named executive officers at the 2024-05-14 meeting.
“Proposal No. 2 The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers by the votes set forth in the table below: Votes For Votes Against Abstentions Broker Non-Votes 54,888,387 3,194,023 879,159 4,262,897”
QuidelOrtho Corp shareholders approved Election of Director: Joseph D. Wilkins Jr. at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Kenneth J. Widder, M.D. at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Matthew W. Strobeck, Ph.D. at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Robert R. Schmidt at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Ann D. Rhoads at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: James R. Prutow at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Mary Lake Polan, M.D., Ph.D., M.P.H. at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Edward L. Michael at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Evelyn S. Dilsaver at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp shareholders approved Election of Director: Kenneth F. Buechler, Ph.D. at the 2024-05-14 meeting.
“☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
QuidelOrtho Corp reported first quarter ended March 31, 2024 results: revenue $711 million, EPS GAAP diluted loss per share for the first quarter of 2024 was $25.50.
“suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer - First Quarter 2024 Results and Recent Highlights • Revenue was $711 million, as reported: ◦ Non-respiratory revenue was flat at $574 million compared to the prior year period, as reported and in constant currency ▪ Excluding the one-time third-party”
Robert J. Bujarski changed role as Interim President at QuidelOrtho Corp.
“each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.”
Michael S. Iskra changed role as Interim Chief Executive Officer at QuidelOrtho Corp.
“each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.”
Brian J. Blaser was appointed as director at QuidelOrtho Corp.
“In addition, effective as of May 15, 2024, the Board expanded its size from ten to eleven directors and appointed Mr. Blaser to serve as a director until the Company’s 2025 Annual Meeting of Stockholders.”
Brian J. Blaser was appointed as President and Chief Executive Officer at QuidelOrtho Corp.
“The Board of Directors (the “Board”) of QuidelOrtho Corporation (the “Company”) has appointed Brian J. Blaser to serve as the Company’s President and Chief Executive Officer, effective as of May 6, 2024 (the “Effective Date”).”
QuidelOrtho Corp amended Amendment No. 2 with Bank of America, N.A., as administrative agent (effective 2024-04-25).
“On April 25, 2024, QuidelOrtho Corporation (the “Company”) entered into Amendment No. 2 (the “Amendment”), by and among the Company, the lenders party thereto, and Bank of America, N.A., as administrative agent, which amends that certain Credit Agreement, dated as of May 27, 2022, as amended by Increase Joinder No. 1, dated as of August 4, 2022, and as further amended by Amendment No. 1, dated as of September 8, 2023”
Robert J. Bujarski was appointed as Interim President at QuidelOrtho Corp.
“and Robert J. Bujarski to serve as the Company’s Interim President, each effective February 21, 2024.”
Michael S. Iskra was appointed as Interim Chief Executive Officer at QuidelOrtho Corp.
“the Board also appointed Michael S. Iskra to serve as the Company’s Interim Chief Executive Officer and Robert J. Bujarski to serve as the Company’s Interim President, each effective February 21, 2024.”
Douglas C. Bryant resigned as Director at QuidelOrtho Corp.
“On February 17, 2024, Mr. Bryant informed the Board of his intent to resign from the Board, effective February 21, 2024.”
Douglas C. Bryant was terminated as President and Chief Executive Officer at QuidelOrtho Corp.
“On February 14, 2024, the Board of Directors (the “Board”) of QuidelOrtho Corporation (the “Company”) determined to terminate Douglas C. Bryant, the Company’s President and Chief Executive Officer, effective February 21, 2024.”
QuidelOrtho Corp updated its fourth quarter and full-year ended December 31, 2023 guidance (initiated).
“On February 13, 2024, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its fourth quarter and full year ended December 31, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on February 13, 2024 to discuss such results.”
James R. Prutow was elected as Director at QuidelOrtho Corp.
“On November 28, 2023, the Board elected Mr. Prutow as a director, effective immediately.”
Stephen H. Wise resigned as Director at QuidelOrtho Corp.
“On November 27, 2023, Stephen H. Wise informed the board of directors (the “Board”) of QuidelOrtho Corporation (the “Company”) of his intent to resign from the Board and as a member of its Nominating and Corporate Governance Committee, effective upon the election of James R. Prutow as a director, which occurred on November 28, 2023 as described below.”
QuidelOrtho Corp reported fiscal year 2023 results: revenue Total revenues (reported) $2.88 - $3.08 billion, EPS Adjusted diluted EPS $4.85 - $5.30. Guidance reaffirmed.
“The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows: Total revenues (reported) $2.88 - $3.08 billion”
QuidelOrtho Corp reported third quarter ended October 1, 2023 results: revenue Third quarter revenue was $744 million, EPS Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90.
“On November 1, 2023, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its third quarter ended October 1, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 1, 2023 to discuss such results.”
QuidelOrtho Corp reported fiscal third quarter ended October 1, 2023 results: revenue $738 million to $744 million. Guidance reaffirmed.
“October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu. Third Quarter 2023 Preliminary Unaudited Revenue Results • Total revenues of $738 million to $744 million; • Non-respiratory product revenue of $557 million to $560 million; and • Respiratory product revenue of $181 million to $184 million. “Our strong performance in”
Christopher M. Smith resigned as Director at QuidelOrtho Corp.
“On August 14, 2023, Christopher M. Smith informed the board of directors (the “Board”) of QuidelOrtho Corporation (the “Company”) of his resignation from the Board, effective as of August 31, 2023, due to other professional commitments.”
QuidelOrtho Corp reported the second quarter ended July 2, 2023 results: revenue $665.1 million.
“today announced financial results for the second quarter ended July 2, 2023. The Company reported total revenue for the second quarter of 2023 of $665.1 million, compared to $613.4 million for the second quarter of 2022. GAAP diluted loss per share (LPS) for the second quarter of 2023 decreased to $(0.80), compared to diluted EPS of $0.36 for the second quarter of 2022.”
QuidelOrtho Corp shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-16 meeting.
“The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's 2023 fiscal year by the votes set forth in the table below: Votes For Votes Against Abstentions 61,369,315 1,237,000 18,729”
QuidelOrtho Corp shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-05-16 meeting.
“The Company's stockholders voted, on an advisory basis, on the frequency of future advisory votes on the compensation of the Company's named executive officers as set forth below: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 58,797,385 66,530 428,739 30,645 3,301,745”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.